Welcome to our dedicated page for Enlivex news (Ticker: ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex stock.
Enlivex Therapeutics Ltd. (ENLV) generates news at the intersection of clinical-stage immunotherapy and digital asset treasury management. Company announcements highlight progress in the development of Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state, and its application in moderate-to-severe knee osteoarthritis. Press releases have detailed positive three- and six-month topline data from the ENX-CL-05-001 Phase I/II trial, including clinically meaningful and statistically significant reductions in pain and improvements in function in age-related primary knee osteoarthritis patients.
Investors following ENLV news will also see updates on Enlivex’s adoption of a digital asset treasury strategy centered on the RAIN token. The company reports that RAIN is the primary asset of its digital asset treasury and describes RAIN as the governance and utility token of a fully decentralized predictions and options protocol built on the Arbitrum network. News items have covered a large private placement intended to fund RAIN token accumulation, an exclusive option agreement to purchase RAIN tokens, and the listing of RAIN on major cryptocurrency exchanges such as KuCoin.
Additional ENLV coverage includes SEC-related disclosures, board and governance changes, shareholder communications, and participation in scientific conferences and investor events. Readers can expect articles on clinical data presentations, new patents related to Allocetra™ in osteoarthritis, shareholder letters outlining strategic roadmaps, and virtual webinars or fireside chats with company leadership and external experts. For those tracking both biotechnology developments in knee osteoarthritis and corporate activity around a RAIN-focused digital asset treasury, the Enlivex news feed provides a consolidated view of the company’s key milestones and strategic decisions.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has partnered with Yale Cancer Center to explore the efficacy of Allocetra™ in combination with immune checkpoint inhibitors to target hard-to-treat solid tumors. This collaboration aims to conduct pre-clinical studies assessing the synergies between Allocetra™ and approved therapies. Enlivex recently reported positive Phase Ib and II results for Allocetra™ in COVID-19 and plans to initiate a Phase IIb study in sepsis. This strategic alliance emphasizes the potential of Allocetra™ to rebalance anti-tumor macrophages in the tumor microenvironment.
Enlivex Therapeutics (Nasdaq: ENLV), a clinical-stage immunotherapy company, announced its participation in two upcoming investor conferences. Management will join the 2nd Annual European Healthtech CEO Forum on March 9, focusing on patient care during the pandemic. They will also present at the H.C. Wainwright Global Life Sciences Conference on March 10, addressing innovative allogeneic cell-based immunotherapy in oncology. Enlivex is developing Allocetra™, a cell therapy aimed at reprogramming macrophages to their homeostatic state, potentially aiding in severe diseases like COVID-19 and solid cancers.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced that the Japan Patent Office has granted a notice of allowance for a new patent covering AllocetraTM, its macrophage reprogramming immunotherapy product. This patent, titled “Combination Immune Therapy and Cytokine Control Therapy for Cancer Treatment,” will protect certain methods and uses of AllocetraTM in conjunction with CAR-T therapies in Japan. The company anticipates the patent will be officially issued in Q2 2021, further strengthening its intellectual property portfolio.
Enlivex Therapeutics Ltd. announced a collaboration with Mount Sinai Health System on March 1, 2021, to explore the use of Allocetra™ in combination with immune-checkpoint inhibitors for treating solid tumors. This pre-clinical program aims to investigate potential synergies between Allocetra™ and approved checkpoint inhibitors, enhancing anti-tumor responses by reprogramming macrophages. Enlivex reported positive interim results from trials involving COVID-19 and sepsis patients, indicating a promising future for Allocetra™ in immunotherapy.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced that the China National Intellectual Property Administration granted a notice of allowance for a new patent covering AllocetraTM, its macrophage reprogramming immunotherapy. This patent will enhance intellectual property protection in China, covering methods and uses for AllocetraTM. The product aims to reprogram macrophages to their homeostatic state, potentially addressing diseases like sepsis, COVID-19, and solid tumors. Issuance of the patent is expected in the coming months.
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced a partial exercise of its bought deal offering, resulting in the purchase of 268,205 ordinary shares at $20.00 each, generating approximately $51.3 million in gross proceeds. The funds will support clinical, regulatory, manufacturing, and R&D activities, along with potential acquisitions. The offering was conducted under an effective shelf registration statement. H.C. Wainwright & Co. served as the book-running manager. The company develops AllocetraTM, an innovative cell therapy aimed at reprogramming macrophages for better immune response.
Enlivex Therapeutics announced the issuance of U.S. Patent No. 10,927,343 for AllocetraTM, its macrophage reprogramming immunotherapy. This patent enhances intellectual property protection for treating autoimmune and inflammatory diseases, including Crohn's disease and ulcerative colitis. While focusing on critical diseases like sepsis and COVID-19, preclinical data suggest AllocetraTM may provide immune rebalancing for unmet medical needs. This development aims to establish a novel therapy mechanism targeting life-threatening conditions.
Enlivex Therapeutics (NASDAQ: ENLV) announced the closure of a public offering of 2,296,107 ordinary shares priced at $20.00 each, generating approximately $45.92 million in gross proceeds. The offering was managed by H.C. Wainwright & Co., which also received a 30-day option to purchase an additional 344,416 shares. Enlivex plans to allocate the net proceeds towards clinical, regulatory, and research activities, as well as potential acquisitions. The company operates under a shelf registration statement with the SEC.
Enlivex Therapeutics (NASDAQ: ENLV) announced an increase in its public offering to 2,296,107 ordinary shares, priced at $20.00 each, due to high demand. The offering is expected to close around February 12, 2021, pending customary closing conditions. Gross proceeds are projected to be approximately $46 million, which will be utilized for clinical, regulatory, and research activities, among other corporate purposes. H.C. Wainwright & Co. will serve as the sole book-running manager for this offering.
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced an underwriting agreement with H.C. Wainwright & Co. to issue 500,000 ordinary shares at $20.00 each, aiming for gross proceeds of $10 million. The offering is set to close around February 12, 2021, subject to customary conditions. The underwriter also has a 30-day option for an additional 75,000 shares. Proceeds will fund clinical and regulatory activities, potential acquisitions, and general corporate purposes. This offering falls under a previously filed shelf registration statement with the SEC, providing liquidity for future endeavors.